Selected data models

You must log in to select data models for download or further analysis.

26 Search results.
Relevance Rating New first Old first

Eligibility NCT01120301 Acute Ischemic Stroke - Eligibility

- 9/27/21 - 1 form, 2 itemgroups, 21 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01120301

Eligibility Stroke NCT00839657

- 9/20/21 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clarification of Optimal Anticoagulation Through Genetics; ODM derived from: https://clinicaltrials.gov/show/NCT00839657

Safety, Pharmacokinetics and Pharmacodynamics of Refanezumab in Patients with Stroke, NCT00833989 - Eligibility Criteria

- 9/20/21 - 1 form, 4 itemgroups, 33 items, 1 language
Itemgroups: Administrative Data, Eligibility question, Inclusion Criteria, Exclusion Criteria
Study ID: 111539 Clinical Study ID: 111539 Study Title: A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of scalating Repeat Doses of GSK249320 in Patients With Stroke Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00833989 https://clinicaltrials.gov/ct2/show/NCT00833989 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Refanezumab, Placebo Trade Name: N/A Study Indication: Ischaemic Attack, Transient The study consists of 8 visits: Day 1, Week 1 (Day 5), Week 2 (Day 10), Week 4 (Day 30), Week 8 (Day 60), Week 12 (Day 90), Week 16 (Day 112), Follow-up (F/U). All subjects will receive two doses. The first dose within 24-72 hrs after stroke the second dose 9 +/- 1 days after the first one. Each dose will be given as an intravenous infusion over 60 minutes. This document contains the eligibility criteria. It has to be filled in at Day 1.

Eligibility NCT00826059 Acute Ischemic Stroke - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 22 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00826059

Eligibility Criteria NCT00044915 - Eligibility NCT00044915

- 9/17/21 - 1 form, 2 itemgroups, 21 items, 2 languages
Itemgroups: Inclusion criteria, Exclusion criteria
see http://clinicaltrials.gov/ct2/show/study/NCT00044915

Eligibility NCT01120301 Acute Ischemic Stroke - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 21 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01120301

Eligibility Stroke NCT01855035

- 6/21/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring; ODM derived from: https://clinicaltrials.gov/show/NCT01855035

Stroke Secondary to Atrial Fibrillation, NCT01925755 - Eligibility Stroke Secondary to Atrial Fibrillation, NCT01925755

- 9/28/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01925755

Eligibility Ischemic Stroke NCT02014896

- 4/27/20 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE); ODM derived from: https://clinicaltrials.gov/show/NCT02014896

Eligibility Embolic Stroke NCT02159287

- 12/4/19 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke; ODM derived from: https://clinicaltrials.gov/show/NCT02159287

Rehabilitation after Stroke using Treadmills NCT01679600 - Eligibility Criteria

- 5/14/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise; ODM derived from: https://clinicaltrials.gov/show/NCT01679600 Brief Summary: The propose of this study is to evaluate the feasibility and the clinical efficiency of feedback-controlled robotics-assisted treadmill exercise (RATE) technology for cardiovascular rehabilitation early after stroke. The investigators hypothesize that feedback-controlled RATE might be suitable and effective to improve cardiovascular fitness and functional carryover in non-ambulatory individuals with sub-acute stroke.

Rehabilitation after Stroke using Treadmills NCT01679600 - Eligibility Criteria NCT01679600

- 5/7/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise; ODM derived from: https://clinicaltrials.gov/show/NCT01679600

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial